Medigene CFO Leaves
This article was originally published in Scrip
Medigene AG's CFO Peter Llewellyn-Davies will be leaving the company after three years – effective March 31, 2016. During his time at Medigene, Llewellyn-Davies contributed to the repositioning of the company towards cancer immunotherapy. He also secured financing for the new corporate strategy through various fund raisings with participation of international investors.